Longeveron (LGVN) EBIT Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBIT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,552.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1,049.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 16,009.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,009.00 |
| Dec 31, 2025 | -76,923.00 |
| Sep 30, 2025 | -473,434.00 |
| Jun 30, 2025 | -96,005.00 |
| Mar 31, 2025 | -61,349.00 |
| Dec 31, 2024 | 792,497.00 |
| Sep 30, 2024 | 283,924.00 |
| Jun 30, 2024 | 188,439.00 |
| Mar 31, 2024 | 94,397.00 |
| Dec 31, 2023 | -430,352.00 |
| Sep 30, 2023 | 174,633.00 |
| Jun 30, 2023 | -172,646.00 |
| Mar 31, 2023 | -59,548.00 |
| Dec 31, 2022 | -240,222.00 |
| Sep 30, 2022 | -307,278.00 |
| Jun 30, 2022 | 12,938.00 |
| Mar 31, 2022 | -17,516.00 |
| Sep 30, 2021 | -206,286.00 |
| Jun 30, 2021 | -62,651.00 |
| Mar 31, 2021 | -90,721.00 |